Carolina Wealth Advisors LLC Has $774,000 Position in Eli Lilly and Company (NYSE:LLY)

Carolina Wealth Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 223.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 937 shares of the company's stock after acquiring an additional 647 shares during the quarter. Carolina Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $774,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Eli Lilly and Company by 182.3% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 797,927 shares of the company's stock worth $659,016,000 after purchasing an additional 515,279 shares in the last quarter. Lafayette Investments Inc. grew its holdings in shares of Eli Lilly and Company by 9.3% during the first quarter. Lafayette Investments Inc. now owns 295 shares of the company's stock worth $244,000 after buying an additional 25 shares in the last quarter. Oakworth Capital Inc. raised its position in shares of Eli Lilly and Company by 0.5% in the first quarter. Oakworth Capital Inc. now owns 3,912 shares of the company's stock valued at $3,231,000 after buying an additional 20 shares during the last quarter. Reston Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 2.4% in the first quarter. Reston Wealth Management LLC now owns 652 shares of the company's stock worth $538,000 after acquiring an additional 15 shares during the last quarter. Finally, Achmea Investment Management B.V. increased its holdings in Eli Lilly and Company by 8.5% in the 1st quarter. Achmea Investment Management B.V. now owns 63,830 shares of the company's stock valued at $52,718,000 after purchasing an additional 4,980 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wall Street Zen downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Saturday. UBS Group dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. Finally, Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $1,011.61.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $4.60 during mid-day trading on Monday, hitting $780.05. The company's stock had a trading volume of 483,711 shares, compared to its average volume of 3,671,138. The stock's 50-day moving average is $780.19 and its two-hundred day moving average is $800.08. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a market capitalization of $739.28 billion, a PE ratio of 63.57, a price-to-earnings-growth ratio of 1.13 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. Eli Lilly and Company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.58 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.